Polpharma Biologics Rebrands As New Warsaw Site Is Validated
First Production Run Expected In Mid-2021
As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”
You may also be interested in...
Polpharma Simplifies Structure By Absorbing Subsidiaries
Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Formycon Shifts Strategy On US Lucentis Biosimilar
Formycon has announced a change of strategy for the FYB201 biosimilar ranibizumab candidate being developed with Bioeq. Both firms insist the change is “not expected to have any impact on the timing of the anticipated launch of FYB201 in the US and EU countries.”